FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2943831157> ?p ?o ?g. }

• W2943831157 abstract "<h3>Background</h3> Long-term survival of stage IV melanoma patients has improved significantly with the development of immune checkpoint inhibitors (CIs). Reliable biomarkers to predict response and clinical outcome are needed. <h3>Methods</h3> We investigated the role of melanoma-associated antibodies as predictive markers for CI therapy in two independent cohorts. In cohort 1, a prospective study, we measured specific antibodies before treatment, after one week and after six to nine weeks of treatment. Cohort 2 consisted of serum samples prior to CI therapy initiation. ELISA assays were performed to quantify specific IgG directed against melanocyte differentiation antigens tyrosinase-related proteins 1 and 2 (TRP1/TYRP1 and TRP2/TYRP2), glycoprotein 100 (gp100), MelanA/MART1, and the cancer-testis antigen NY-ESO-1. Response was defined as either complete or partial remission on CT scan according to RECIST 1.1. <h3>Results</h3> In cohort 1, baseline levels of these antibodies were higher in the responder group, although statistical significance was only reached for NY-ESO-1 (<i>p</i> = 0.007). In cohort 2, significantly higher antibody baseline levels for MelanA/MART1 (<i>p</i> = 0.003) and gp100 (<i>p</i> = 0.029) were found. After pooling the results from both cohorts, higher levels of MelanA/MART1 (<i>p</i> = 0.013), TRP1/TYRP1 (<i>p</i> = 0.048), TRP2/TYRP2 (<i>p</i> = 0.047) and NY-ESO-1 (<i>p</i> = 0.005) specific antibodies at baseline were independently associated with response. <h3>Conclusions</h3> Melanoma-associated antibodies may be candidate biomarkers for response and survival in metastatic melanoma patients being treated with CIs. These markers may be used to complement patient assessment, in combination with PD-L1 status, tumor-infiltrating lymphocytes and tumor mutational burden, with the aim to predict outcome of CI treatment in patients with metastatic melanoma. <h3>Trial registration</h3> Ethikkommission Ostschweiz, EKOS 16/079 https://ongoingprojects.swissethics.ch/runningProjects_list.php?q=%28BASECID~contains~2016-00998%29&orderby=dBASECID." @default.
• W2943831157 created "2019-05-09" @default.
• W2943831157 creator A5017247203 @default.
• W2943831157 creator A5020708921 @default.
• W2943831157 creator A5022167252 @default.
• W2943831157 creator A5022387169 @default.
• W2943831157 creator A5026194740 @default.
• W2943831157 creator A5027395430 @default.
• W2943831157 creator A5031118170 @default.
• W2943831157 creator A5036602887 @default.
• W2943831157 creator A5037839310 @default.
• W2943831157 creator A5038189709 @default.
• W2943831157 creator A5039593933 @default.
• W2943831157 creator A5046999081 @default.
• W2943831157 creator A5052572303 @default.
• W2943831157 creator A5062829189 @default.
• W2943831157 creator A5063337645 @default.
• W2943831157 creator A5064134027 @default.
• W2943831157 creator A5079146691 @default.
• W2943831157 creator A5082278497 @default.
• W2943831157 creator A5084754410 @default.
• W2943831157 creator A5087984672 @default.
• W2943831157 creator A5089297467 @default.
• W2943831157 creator A5090698825 @default.
• W2943831157 date "2019-02-20" @default.
• W2943831157 modified "2023-10-01" @default.
• W2943831157 title "Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients" @default.
• W2943831157 cites W1809627231 @default.
• W2943831157 cites W1883154993 @default.
• W2943831157 cites W1914337318 @default.
• W2943831157 cites W1962181166 @default.
• W2943831157 cites W1965215390 @default.
• W2943831157 cites W1969809230 @default.
• W2943831157 cites W1970297719 @default.
• W2943831157 cites W1981197892 @default.
• W2943831157 cites W1986046751 @default.
• W2943831157 cites W1987155779 @default.
• W2943831157 cites W2008229215 @default.
• W2943831157 cites W2008494452 @default.
• W2943831157 cites W2019607817 @default.
• W2943831157 cites W2036392773 @default.
• W2943831157 cites W2039123767 @default.
• W2943831157 cites W2042293669 @default.
• W2943831157 cites W2044928979 @default.
• W2943831157 cites W2056964537 @default.
• W2943831157 cites W2097995306 @default.
• W2943831157 cites W2107863654 @default.
• W2943831157 cites W2112121482 @default.
• W2943831157 cites W2124981160 @default.
• W2943831157 cites W2127737941 @default.
• W2943831157 cites W2128035403 @default.
• W2943831157 cites W2130184077 @default.
• W2943831157 cites W2133075384 @default.
• W2943831157 cites W2137088550 @default.
• W2943831157 cites W2141745968 @default.
• W2943831157 cites W2144223273 @default.
• W2943831157 cites W2144304036 @default.
• W2943831157 cites W2148368831 @default.
• W2943831157 cites W2148830146 @default.
• W2943831157 cites W2150835657 @default.
• W2943831157 cites W2152897456 @default.
• W2943831157 cites W2153712501 @default.
• W2943831157 cites W2154042746 @default.
• W2943831157 cites W2156000007 @default.
• W2943831157 cites W2157860451 @default.
• W2943831157 cites W2166662937 @default.
• W2943831157 cites W2167279371 @default.
• W2943831157 cites W2168572010 @default.
• W2943831157 cites W2172131454 @default.
• W2943831157 cites W2262266664 @default.
• W2943831157 cites W2346108121 @default.
• W2943831157 cites W2396808887 @default.
• W2943831157 cites W2533262657 @default.
• W2943831157 cites W2534772180 @default.
• W2943831157 cites W2560367415 @default.
• W2943831157 cites W2572174216 @default.
• W2943831157 cites W2605085812 @default.
• W2943831157 cites W2621027006 @default.
• W2943831157 cites W2753432434 @default.
• W2943831157 cites W2770275299 @default.
• W2943831157 cites W2782372774 @default.
• W2943831157 cites W2783417222 @default.
• W2943831157 cites W2889190248 @default.
• W2943831157 doi "https://doi.org/10.1186/s40425-019-0523-2" @default.
• W2943831157 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6383238" @default.
• W2943831157 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30786924" @default.
• W2943831157 hasPublicationYear "2019" @default.
• W2943831157 type Work @default.
• W2943831157 sameAs 2943831157 @default.
• W2943831157 citedByCount "40" @default.
• W2943831157 countsByYear W29438311572019 @default.
• W2943831157 countsByYear W29438311572020 @default.
• W2943831157 countsByYear W29438311572021 @default.
• W2943831157 countsByYear W29438311572022 @default.
• W2943831157 countsByYear W29438311572023 @default.
• W2943831157 crossrefType "journal-article" @default.
• W2943831157 hasAuthorship W2943831157A5017247203 @default.
• W2943831157 hasAuthorship W2943831157A5020708921 @default.
• W2943831157 hasAuthorship W2943831157A5022167252 @default.
• W2943831157 hasAuthorship W2943831157A5022387169 @default.

• next